Novartis AG ADR (NVS)vsProgyny Inc (PGNY)
NVS
Novartis AG ADR
$158.83
-0.25%
HEALTHCARE · Cap: $290.96B
PGNY
Progyny Inc
$31.37
+1.98%
HEALTHCARE · Cap: $2.50B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 4284% more annual revenue ($56.69B vs $1.29B). NVS leads profitability with a 22.5% profit margin vs 5.2%. NVS trades at a lower P/E of 22.0x. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
PGNY
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.7%
Fair Value
$92.54
Current Price
$158.83
$66.29 premium
Intrinsic value data unavailable for PGNY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Earnings expanding 70.6% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
1.4% revenue growth
5.2% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bull Case : PGNY
The strongest argument for PGNY centers on EPS Growth, Debt/Equity, Altman Z-Score.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : PGNY
The primary concerns for PGNY are Revenue Growth, Profit Margin, Piotroski F-Score. A P/E of 41.5x leaves little room for execution misses.
Key Dynamics to Monitor
PGNY carries more volatility with a beta of 1.02 — expect wider price swings.
PGNY is growing revenue faster at 1.4% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 50/100), backed by strong 22.5% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Progyny Inc
HEALTHCARE · HEALTHCARE PLANS · USA
Progyny, Inc., a benefits management company, specializes in fertility benefits and family development solutions for employers in the United States. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?